Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: macitentan Clear all
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01841762
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00667823
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03714815
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Interventions
macitentan 10 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 4 Interventional Results available

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

NCT02885012
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 1 Interventional

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

NCT02254954
View directory record Official record
Conditions
Glioblastoma
Interventions
Macitentan in combination with RT and TMZ
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 4, 2026, 6:30 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Results available

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

NCT05373108
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 6:30 PM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 4 Interventional

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

NCT04955990
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PAH Therapies
Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
macitentan (ACT-064992), placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
View directory record Official record
Conditions
Healthy
Interventions
Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

NCT01847014
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 3 Interventional Results available

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

NCT03775421
View directory record Official record
Conditions
Congenital Heart Disease With Fontan Circulation
Interventions
macitentan 10 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

NCT00903331
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ACT-064992 (macitentan), Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 3 Interventional

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

NCT05140525
View directory record Official record
Conditions
CTEPH
Interventions
Macitentan Tablets, Riociguat, balloon pulmonary angioplasty
Drug · Device
Lead sponsor
Dr Sudarshan Rajagopal
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

NCT02070991
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Louisville, Kentucky • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 4, 2026, 6:30 PM EDT
Withdrawn Phase 3 Interventional

Macitentan to Prevent PRVO

NCT05946811
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Macitentan 10mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 4, 2026, 6:30 PM EDT
Terminated Phase 2 Interventional Results available

Macitentan in Pulmonary Hypertension of Sickle Cell Disease

NCT02651272
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease
Interventions
macitentan
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 4, 2026, 6:30 PM EDT
Completed No phase listed Observational

OPsumit USers Registry

NCT02126943
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Opsumit (macitentan)
Drug
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
144
States / cities
Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 4, 2026, 6:30 PM EDT
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 6:30 PM EDT